High infectious risk donors: What are the risks and when are they too high?

Current Opinion in Organ Transplantation

Volumn 16, Issue 2, 2011, Pages 256-261

  Kucirka, Lauren M ^a   Singer, Andrew L ^a   Segev, Dorry L ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Deceased donor transplantation; high risk donor; HIV; nucleic acid testing; organ utilization

Indexed keywords

ARTICLE; DISEASE TRANSMISSION; DONOR; HEALTH CARE UTILIZATION; HEPATITIS C VIRUS; HIGH INFECTIOUS RISK DONOR; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION RISK; NUCLEIC ACID ANALYSIS; PATIENT ATTITUDE; VIRUS TRANSMISSION;

COMMUNICABLE DISEASES; DONOR SELECTION; HUMANS; INFORMED CONSENT; ORGAN TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TISSUE DONORS; TREATMENT OUTCOME; WAITING LISTS;

EID: 79954600713     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283449dd3     Document Type: Article

References (49)

1. United Network for Organ Sharing Sharing. 2009 Organ Procurement and Transplant Network/Scientific Registry of Transplant Recipients Annual Report. Health Resources and Services Center.
2. United States Renal Data System. 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End Stage Renal Disease in the United States, Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive Kidney Diseases.
3. Kucirka LM, Dagher NN, Montgomery RA, Segev DL, Singer AL. High infectious risk organ donors in kidney transplantation: risks, benefits, and current practices. Dial Transplant 2010; 39:186-189.
4. Rogers MF, Simonds RJ, Lawton KE, et al. National Center for Infectious Diseases. Guidelines for preventing transmission of human immunodeficiency virus through transplantation of human tissue and organs. MMWR 1994; 43:1-17. http://www.cdc.gov/MMWR/preview/mmwrhtml/ 00031670.htm. [Accessed 5 February 2008]
5. Provisional Public Health Service interagency recommendations for screening donated blood and plasma for antibody to the virus causing acquired immunodeficiency syndrome. http://www.cdc.gov/mmwr/preview/mmwrhtml/00033029. htm. [Accessed 12 September 2008].
6. United Network for Organ Sharing. Communication of donor history. United Network for Organ Sharing Web site. http://optn.transplant.hrsa.gov/ PoliciesandBylaws2/policies/pdfs/policy-16.pdf. [Accessed 11 November 2010].
7. Kucirka LM, Alexander C, Namuyinga R, et al. Viral nucleic acid testing (NAT) and OPO-level disposition of high-risk donor organs. Am J Transplant 2009; 9:620-628.
8. Kucirka LM, Namuyinga R, Hanrahan C, et al. Provider utilization of high-risk donor organs and nucleic acid testing: results of two national surveys. Am J Transplant 2009; 9:1197-1204.
9. Duan KI, Englesbe MJ, VolkML. Centers for Disease Control 'high-risk' donors and kidney utilization. Am J Transplant 2010; 10:416-420.
10. Minimum Procurement Standards for an Organ Procurment Organization. 2008 [cited 2008 September 12]. http://www.unos.org/PoliciesandBylaws2/ policies/pdfs/policy-2.pdf.
11. Ahn J, Cohen SM. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl 2008; 14:1603-1608.
12. Apperley JF, Rice SJ, Hewitt P, et al. HIV infection due to a platelet transfusion after allogeneic bone marrow transplantation. Eur J Haematol 1987; 39:185-189.
13. Erice A, Rhame FS, Heussner RC, et al. Human immunodeficiency virus infection in patients with solid-organ transplants: report of five cases and review. Rev Infect Dis 1991; 13:537-547.
14. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-1879. (Pubitemid 37070272)
15. Pereira BJ,Wright TL, Schmid CH, Levey AS. A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet 1995; 345:484-487.
16. Busch MP, Lee LL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995; 35:91-97.
17. Fishman JA, Greenwald MA, Kuehnert MJ. Enhancing transplant safety: a new era in the microbiologic evaluation of organ donors? Am J Transplant 2007; 7:2652-2654. (Pubitemid 350045788)
18. Hardy WD Jr. General principles of retrovirus immunodetection tests. J Am Vet Med Assoc 1991; 199:1282-1287.
19. Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45:254-264. (Pubitemid 40180144)
20. Owen SM, Yang C, Spira T, et al. Alternative algorithms for human immunodeficiency virus infection diagnosis using tests that are licensed in the United States. J Clin Microbiol 2008; 46:1588-1595. (Pubitemid 351657199)
21. Assal A, Barlet V, Deschaseaux M, et al. Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels. Transfusion 2009; 49:301-310.
22. Marshall DA, Kleinman SH, Wong JB, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and humanimmunodeficiency virusin theUnitedStates. VoxSang2004;86:28-40. (Pubitemid 38200453)
23. Humar A, Morris M, Blumberg E, et al. Nucleic acid testing (NAT) of organ donors: is the 'best' test the right test? A consensus conference report. Am J Transplant 2010; 10:889-899.
24. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006; 36 (Suppl 1):S23-S29. (Pubitemid 44016154)
25. Zou S, Stramer SL, Notari EP, et al. Current incidence and residual risk of hepatitis B infection among blood donors in the United States. Transfusion 2009; 42:1609-1620.
26. Borst A, Box AT, Fluit AC. False-positive results and contamination in nucleic acid amplification assays: suggestions for a prevent and destroy strategy. Eur J Clin Microbiol Infect Dis 2004; 23:289-299. (Pubitemid 38669939)
27. Reese PP, Feldman HI, Asch DA, et al. Transplantation of kidneys from donors at increased risk for blood-borne viral infection: recipient outcomes and patterns of organ use. Am J Transplant 2009; 9:2338-2345.
28. Lonze EB, Liu M, Kucirka LM, et al. Outcomes of renal transplants from CDC high-risk donors with prospective recipient viral testing: a single-center experience. Arch Surg 2011; (in press).
29. Bucci JR, Lentine KL, Agodoa LY, et al. Outcomes associated with recipient and donor hepatitis C serology status after kidney transplantation in the United States: analysis of the USRDS/UNOS database. Clin Transpl 2004:51-61.
30. Bucci JR, Matsumoto CS, Swanson SJ, et al. Donor hepatitis C seropositivity: clinical correlates and effect on early graft and patient survival in adult cadaveric kidney transplantation. J Am Soc Nephrol 2002; 13:2974-2982. (Pubitemid 35386917)
31. Locke JE, Montgomery RA, Warren DS, et al. Renal transplant in HIV-positive patients: long-term outcomes and risk factors for graft loss. Arch Surg 2009; 144:83-86.
32. Stock PG, Roland ME. Evolving clinical strategies for transplantation in the HIV-positive recipient. Transplantation 2007; 84:563-571. (Pubitemid 47429035)
33. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363:2004-2014.
34. Kucirka LM, Singer AL, Ros RL, et al. Underutilization of hepatitis C-positive kidneys for hepatitis C-positive recipients. Am J Transplant 2010; 10:1238-1246.
35. Muller E, Kahn D, Mendelson M. Renal Transplantation between HIV-positive donors and recipients. N Engl J Med 2010; 362:2336-2337.
36. Schweitzer EJ, Perencevich EN, Philosophe B, Bartlett ST. Estimated benefits of transplantation of kidneys from donors at increased risk for HIV or hepatitis C infection. Am J Transplant 2007; 7:1515-1525. (Pubitemid 46776240)
37. Grady D. Four transplant recipients contract HIV. New York: New York Times; 2007.
38. Kucirka LR, RL; Subramanian, AK; Montgomery, RA; Segev, DL. Provider response to a rare but highly publicized transmission of HIV through solid organ transplantation. Arch Surg 2011; 146:41-45.
39. Kucirka LM, Namuyinga R, Hanrahan C, et al. Formal policies and special informed consent are associated with higher provider utilization of CDC highrisk donor organs. Am J Transplant 2009; 9:629-635.
40. Halpern SD, Shaked A, Hasz RD, Caplan AL. Informing candidates for solidorgan transplantation about donor risk factors. N Engl J Med 2008; 358: 2832-2837.
41. Fishman JA. Informing candidates for transplantation about donor risk factors. N Engl J Med 2008; 359:1182; author reply: 3.
42. Freeman RB, Cohen JT. Transplantation risks and the real world: what does 'high risk' really mean? Am J Transplant 2009;9:23-30.
43. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 2003; 289:959-962. (Pubitemid 37432916)
44. Botte C, Janot C. Epidemiology of HCV infection in the general population and in blood transfusion. Nephrol Dial Transplant 1996; 11 (Suppl 4):19-21. (Pubitemid 26345099)
45. Dosekun O, Fox J. An overview of the relative risks of different sexual behaviours on HIV transmission. Curr Opin HIV AIDS 2010; 5:291-297.
46. Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period HIV infection in high risk donors: systematic review and meta-analysis. Am J Transplant 2011; (in press).
47. Kucirka LM, Sarathy H, Govindan P, et al. Risk of window period HCV infection in high risk donors: systematic review and meta-analysis. Am J Transplant (in press).
48. Reese PP, Tehrani T, Lim MA, et al. Determinants of the decision to accept a kidney from a donor at increased risk for blood-borne viral infection. Clin J Am Soc Nephrol 2010; 5:917-923.
49. Lipoldova M, Boylston AW, Yssel H, Owen MJ. T-cell receptor V beta 5 usage defines reactivity to a human T-cell receptor monoclonal antibody. Immunogenetics 1989; 30:162-168. (Pubitemid 19226615)